Profiel
Tony Eglezos is currently the Vice President-Business Development at Starpharma Holdings Ltd. He previously worked as the Senior Director-Business Development & Licensing at CSL Ltd. from 2006 to 2013 and as the Director-Commercial Operations & Pharmaceuticals at Seqirus Pty Ltd. from 2010 to 2013.
Dr. Eglezos holds a doctorate degree from the University of Melbourne and an MBA from the University of Technology Sydney.
Actieve functies van Tony Eglezos
| Bedrijven | Functie | Begin |
|---|---|---|
| STARPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 12-08-2013 |
Eerdere bekende functies van Tony Eglezos
| Bedrijven | Functie | Einde |
|---|---|---|
Seqirus Pty Ltd.
Seqirus Pty Ltd. BiotechnologyHealth Technology Develops and manufactures vaccines & plasma protein biotherapies | Corporate Officer/Principal | 01-08-2013 |
| CSL LIMITED | Corporate Officer/Principal | 01-08-2013 |
Opleiding van Tony Eglezos
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
CSL Ltd.
CSL Ltd. BiotechnologyHealth Technology Develops and manufactures medicines that treat people with rare and serious diseases | Health Technology |
Starpharma Holdings Ltd.
Starpharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research and development of dendrimer products for pharmaceutical, life science & other applications | Health Technology |
University of Melbourne
University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Technology Sydney
University of Technology Sydney Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seqirus Pty Ltd.
Seqirus Pty Ltd. BiotechnologyHealth Technology Develops and manufactures vaccines & plasma protein biotherapies | Health Technology |
















